IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer

RTTNews | 1023 dias atrás
IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer

(RTTNews) - Oncology company IDEAYA Biosciences, Inc. (IDYA) announced that Darrin Beaupre has joined the company as its Chief Medical Officer, effective November 21, 2022.

Beaupre's extensive career includes various clinical development and translational research roles in industry, including most recently at BioSplice Therapeutics as Chief Medical Officer and Head of Research and Development in Oncology.

Beaupre previously served as Senior Vice President, Head of Early Oncology Development and Clinical Research at Pfizer, Inc., where he led cross-disciplinary groups including clinical development, clinical pharmacology, translational oncology and clinical operations related study clinicians.

Beaupre also served at Pharmacyclics (Abbvie) as Vice President, Head of Early Development and Immunotherapy, and at Amgen as Medical Director.

He was previously an Assistant Professor at the H. Lee Moffitt Cancer Center and Research Institute, and also held various earlier appointments at the University of Miami and the M.D. Anderson Cancer Center.

Etiquetas: IDYA
read more
IDEAYA Biosciences Q4 Results Misses Estimates

IDEAYA Biosciences Q4 Results Misses Estimates

IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, announced net loss of $32.64 million or $0.52 per share, wider than $23.07 million or $0.50 per share in the prior-year quarter.
RTTNews | 574 dias atrás
IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

Oncology company IDEAYA Biosciences, Inc. (IDYA) announced Monday the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a GSK-sponsored Phase 1/2 clinical trial to evaluate GSK101 (IDE705) for the treatment of patients having tumors with BRCA or other homologous recombination (HR) mutations or homologous recombination deficiency (HRD).
RTTNews | 757 dias atrás
DAX Drifts Lower Ahead Of Fed Policy Meeting

DAX Drifts Lower Ahead Of Fed Policy Meeting

German stocks are down in negative territory on Tuesday with investors mostly staying cautious, focusing on the Federal Reserve's monetary policy meeting, which gets underway today, and the ongoing trade talks between China and the U.S.
RTTNews | 16 minutos atrás
German Economic Sentiment Rises In September

German Economic Sentiment Rises In September

German economic confidence improved in September but financial market experts remained cautiously optimistic, a monthly survey conducted by the think tank ZEW showed on Tuesday. The ZEW indicator of economic confidence rose unexpectedly to 37.3 in September from 34.7 in the previous month. The score was expected to fall to 27.3.
RTTNews | 25 minutos atrás
European Shares Subdued Ahead Of Fed Meeting

European Shares Subdued Ahead Of Fed Meeting

European stocks were flat to slightly lower on Tuesday and the U.S. dollar slipped to an over two-month low ahead of the start of a two-day policy meeting of the Federal Reserve later in the day, with traders eyeing a widely expected 25 bps rate cut.
RTTNews | 1 h 59 min atrás
U.S. Dollar Falls Amid Fed Rate Cut Speculation

U.S. Dollar Falls Amid Fed Rate Cut Speculation

The U.S. dollar weakened against other major currencies in the Asian session on Tuesday, as traders have already factored in a rate cut by the US Fed as a "certainty."
RTTNews | 2 h 20 min atrás